Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (May 2026)
21 slides from Imagion Biosystems's investor presentation, May 26, 2026
Slide 1: Molecular MRI: The Next Generation of Imaging
B R E A KT H RO U G H FO R E A R LY CA N C E R D E T ECT I O N For personal use only Molecular MRI: The Next Generation of Imaging Imagion Biosystems Limited ASX: IBX
Slide 2: Forward Looking Statements
Fo r w a rd L o o k i n g S t at e m e n t s This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current Company). This presentation does not cons
Slide 3: Company Overview
Company Overview For personal use only A clinical-stage medical imaging company developing a new class of molecularly targeted imaging agents for the early detection of cancer.
Slide 4: MagSense Molecular Imaging
COMPANY OVERVIEW MagSense® Molecular Imaging For personal use only • Next generation tech to disrupt radiopharmaceuticals • Improving cancer detection compared to conventional imaging technologies by leveraging molecular specificity without radioactivity • Highly differentiated and first-of-its-kind
Slide 5: Upcoming Key Milestones
COMPANY OVERVIEW Upcoming Key Milestones For personal use only Submission to the US FDA of Commencement of a Phase 2 Study Investigational New Drug (IND) for the MagSense® HER2 imaging application completed April agent to follow FDA approval of the 2026. IND, which is anticipated in Q2 ‘26 5
Slide 6: The Next Generation of Molecular Imaging
The Next Generation of Molecular Imaging For personal use only RADIOPHARMACEUTICALS & NON-RADIOPHARMACEUTICAL CONTRAST MEDIA MARKET LEADERS THERANOSTICS Contrast Enhanced MRI PET MagSense® mMRI ✓ Gadolinium-Based Contrast Agents ✓ High sensitivity ✓ No radioactivity: may improve safety improve contr
Slide 7: Speed and Accuracy of Initial Diagnosis is Key
Speed and Accuracy of Initial Diagnosis is Key For personal use only 5 -Y E A R S U R V I VA L R AT E D E P E N D I N G O N E A R LY O R L AT E D I A G N O S I S : ² Prostate Cancer Ovarian Cancer 100% 28% 92% 27% Over 50% of cancers are Early Late Early Late diagnosed at late stage¹ Breast Cancer L
Slide 8: Current Diagnosis Takes Too Long
SPEED AND ACCURACY OF INITIAL DIAGNOSIS IS KEY Current Diagnosis Takes Too Long For personal use only Screening • Blood-based tests indicate risk but are non-diagnostic and require confirmation before treatment Biopsy • Provide certainty but are invasive, painful, error prone and challenging, often
Slide 9: What is MagSense
What is MagSense® IBX’s MagSense is designed to bind only to specific cancer cells when administered systemically or regionally For personal use only + + + Magnetite Nanoparticle Core Protective Polymer Coating Stealth Coating Targeting Moieties Superparamagnetic iron oxide Biocompatible coating to
Slide 10: Earlier, More Accurate Cancer Detection
WHAT IS MAGSENSE® Earlier, More Accurate Cancer Detection For personal use only PRE-DOSE POST-DOSE MagSense® precision combined with MRI’s high resolution delivers clearer, more confident imaging to support earlier, more definitive diagnoses. MagSense particles are coated with unique ~30% CHANGE IN
Slide 11: Changing How We See Cancer
WHAT IS MAGSENSE® Changing How We See Cancer For personal use only Specific MRI-based Detection • Aims to provides molecular confirmation • Compatible across 50k+ MRI scanners of cancer, not just “suspicion” in use globally Improved Patient Safety Platform Technology • No radioactivity • Fits clinic
Slide 12: Phase 1 Trial: Molecular MRI for Detection of Axillary Nodal Metastasis
CLINICAL TRIALS Phase 1 Trial: Molecular MRI for the Detection of Axillary Nodal Metastasis For personal use only in Subjects Met All Endpoints 1 Baseline Post-MagSense® • Phase 1 trial conducted in patients with HER2+ breast cancer (N=13) • Imaging agent was generally safe and well tolerated in all
Slide 13: The Phase 2 HER2+ Clinical Trial
CLINICAL TRIALS The Phase 2 HER2+ Clinical Trial Investigating the Pharmacokinetics, Dosage, Imaging Schedule, and Diagnostic Performance of the MagSense® HER2 For personal use only Imaging Agent Using Magnetic Resonance Imaging in Participants with HER2+ Breast Cancer for the Assessment of Tumor In
Slide 14: MagSense Imaging Agents Can Be Applied to Many Types of Cancer
PLATFORM TECHNOLOGY – ADDITIONAL INDICATIONS MagSense® Imaging Agents Can Be Applied to Many Types of Cancer For personal use only Pre-Dose Post-Dose • All MagSense agents work the same, making the regulatory path clear and commercialization and adoption easier • Changing the MagSense targeting mole
Slide 15: MagSense Upside: Next Generation AI Learning
MagSense® Upside: Next Generation AI learning For personal use only Unique quantitative signature may allow for Artificial Intelligence and Machine Learning algorithms for automated detection One of the most transformative applications of artificial intelligence in oncology is its role in enhancing
Slide 16: Addressing Large, Growing Markets
Addressing Large, Growing Markets CANCER DIAGNOSTICS - $100B MARKET For personal use only 7% CAGR2 Chances are, you know at $30,000 $26,044 least one person who has $25,000 $20,136 Millions been personally affected by $20,000 $15,541 $15,000 cancer $10,000 $7,246 $8,850 $9,632 $5,908 $3,055 $4,583 $
Slide 17: Comparable Market Peer Transactions
STRATEGIC PARTNERING OPPORTUNITY Comparable Market Peer Transactions For personal use only Incumbents continue making attractive deals for differentiated clinical-stage assets Acquirer Target Value AUD Year Notes Acquisition Structure • Imuno-oncology agent $1.6B 2018 • Acquired following successful
Slide 18: IBX Clinical Development Strategy
IBX CLINICAL DEVELOPMENT STRATEGY Key Clinical Pathways 2026/27 For personal use only Key Next Steps Core Focus 1. IND filed April 2026 HER2+ Breast Cancer Pre-Clinical Phase 1 IND Phase 2 Dose and Image Protocol Optimisation 2. Initiate Phase 2 HER2+ Breast Cancer study following IND acceptance Sec
Slide 19: Investment Rationale
Investment Rationale LARGE MARKETS WITH AN UNMET MEDICAL NEED REDUCED TECHNICAL RISK For personal use only UPSIDE LEVERAGE • Global cancer incidence to rise • High rate of contrast media • Large ASX Peer Valuations, 77% by 2050 with screening & products achieve regulatory Potential for Strategic Par
Slide 20: Company and Leadership
Company and Leadership For personal use only Robert Proulx MAICD Melanie Leydin CA FGIA Nina Webster PhD, MBA, M.IP.Law Brett Mitchell Executive Chairman Co.Sec. and Non-Executive Director Non-Executive Director Non-Executive Director Robert is an operationally oriented executive with over Melanie i
Slide 21: Ticker Symbol and Contact
For personal use only TICKER SYMBOL ASX: IBX Cash Balance1 $1.85MM (AUD) Market Capitalisation2 $7.36MM (AUD) Share Price2 $0.015 (AUD) Total Ordinary Shares 490,590,239 A BREAKTHROUH FOR on Issue2 E A R LY C A N C E R D E T ECT I O N Average 90-Day Liquidity by Volume2 3,160,200 1. As at 31 Decembe
Imagion Biosystems — Investor Presentation (May 2026) on 6ix